Disease quiescence in endophthalmitis patients treated with anti-VEGF injections for retinal pathologies

BMC Ophthalmology

Table 1 Patient characteristics

No.	Gender	Background systemic condition	Laterality	Diagnosis	Anti-VEGF compound	BCVA at presentation	No. of Years on treatment before	Management	Vitreous sample culture growth
1	M		RE	Myopic CNV	Bevacizumab	HM	3	tap and inject + vitrectomy	Staphylococcus Epidermitis
2	M		RE	NVAMD	Aflibercept	0.08	4	tap and inject + vitrectomy	Staphylococcus Epidermitis
3	M	HTN, CHD	RE	RVO	Bevacizumab	HM	9	tap and inject + vitrectomy	Staphylococcus Epidermitis
4	F	HTN, CHD	LE	NVAMD	Ranibizumab	0.25	2	tap and inject	negative
5	M		RE	NVAMD	Bevacizumab	HM	5	tap and inject	negative
6	M		RE	NVAMD	Bevacizumab	HM	1	tap and inject + vitrectomy	negative
7	F	DMII	RE	DME	Aflibercept	0.5	4	tap and inject + vitrectomy	negative
8	M		LE	NVAMD	Ranibizumab	0.22	1	tap and inject + vitrectomy	Staphylococcus Epidermidis
9	F	DMII	LE	NVAMD	Ranibizumab	0.25	3	tap and inject	Staphylococcus Epidermidis
10	M	DMII, HTN	RE	DME	Aflibercept	0.3	1	tap and inject + vitrectomy	Staphylococcus Epidermidis
10	M	DMII, HTN	LE	DME	Bevacizumab	CF	2	tap and inject + vitrectomy	Staphylococcus Epidermidis

Anti-VEGF, anti-vascular endothelial risk factor; BCVA, best-corrected visual acuity; M, male; F, female; RE, right eye; LE, left eye; HNT, hypertension; CHD, coronary heart disease; DMII, diabetes mellitus type 2; NVAMD, neovascular age related macular degeneration; RVO, retinal vein occlusion; DME, diabetic macular edema; CNV choroidal neovascularization; hand-motion, HM; counting fingers, CF

ISSN: 1471-2415